Leads Biolabs announced that its PD-L1/4-1BB bispecific antibody, Opamtistomig, has advanced to the expansion stage in a Phase II trial for first-line treatment of advanced gastric cancer. This stage will compare Opamtistomig plus chemotherapy directly with the current standard, tislelizumab plus chemotherapy, aiming to improve outcomes especially for patients with low PD-L1 expression who respond poorly to existing therapies. The study, led by Peking University Cancer Hospital, seeks to identify patient groups most likely to benefit and could offer a new, more effective immunotherapy option for this challenging cancer type. Opamtistomig's unique mechanism activates T cells regardless of PD-L1 levels, potentially overcoming limitations of current treatments.
Leads Biolabs' Opamtistomig development is noted alongside Health-sector market activity on Pluang. For readers following Health stocks, here is Pluang's market snapshot as of Oct 20, 2026 17:01 WIB: out of 150 priced Health-sector US stocks, 78 rose and 62 fell. Notable movers include AstraZeneca plc (AZN) at USD 166.85 with a Pluang order activity of 13% Sell / 87% Buy and a typical hold time of 126 Days, Tango Therapeutics Inc. (TNGX) at USD 23.10 with a 1-day change of -1.83%, and Nuvation Bio Inc. Class A (NUVB) at USD 4.40 with a 1-day change of -1.79%.
RoyaLand Company Ltd. announced Palazzo Chronicles, a free-to-play mobile match-3 puzzle game set in 19th-century Piedmont during Italy's reunification. Players help Adelaide restore her inherited family castle by solving puzzles and rebuilding rooms...
Route 92 Medical has secured a $100 million senior secured debt facility from Trinity Capital to strengthen its balance sheet and support ongoing product innovation and commercial growth. The funding will help the company expand its neurovascular int...
First Federal Savings Bank marks its 122nd anniversary, highlighting over a century of service to Southwest Indiana and Western Kentucky. The bank has grown from a single community institution to ten locations, focusing on personal service, local dec...
Aclarion, Inc. announced an 85% year-over-year increase in scan volumes for Q3 2026, contributing to a 117% growth for the first nine months of the year. The company highlighted the publication of supportive clinical data in the European Spine Journa...
The global electric vehicle (EV) components market is projected to grow from $486.4 billion in 2026 to $1.28 trillion by 2036, expanding at a 10.2% CAGR. Growth is fueled by rising EV adoption, advancements in battery systems, power electronics, and ...
